Related Experiment Video
Updated: Jun 23, 2026
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Cystic fibrosis: pathogenesis and future treatment strategies
1Division of Respiratory Medicine, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8. felix.ratjen@sickkids.ca
Abstract:
Since the detection of the underlying gene defect, our knowledge of how the genetic mutations in cystic fibrosis cause lung disease has increased substantially, but we still lack a complete understanding of some of the pieces in the puzzle. Nevertheless, the information gained has led to new therapeutic approaches that address key factors of cystic fibrosis pathophysiology. Past therapeutic successes were largely based on targeting the consequences of the cystic fibrosis transmembrane regulator dysfunction, such as phlegm retention, infection, and inflammation, but new therapies may be able to address the underlying abnormality rather than its downstream effects. The efficacy of these treatments still needs to be established, but early studies look promising for several compounds. This review summarizes our current understanding of the pathophysiology and treatment of cystic fibrosis lung disease.
Insights
Cystic fibrosis (CF) research has advanced understanding of genetic mutations causing lung disease. New therapies aim to correct the underlying CFTR defect, offering promising alternatives to managing symptoms.
Area of Science:
- Pulmonary Medicine
- Genetics
- Pharmacology
Background:
- Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CFTR gene.
- CF leads to progressive lung disease characterized by inflammation, infection, and mucus buildup.
- While the genetic basis is known, the precise mechanisms of lung damage are still being elucidated.
Purpose of the Study:
- To review the current understanding of cystic fibrosis lung disease pathophysiology.
- To summarize emerging therapeutic strategies targeting the root cause of CF.
- To discuss the shift from managing consequences to addressing the underlying genetic defect.
Main Methods:
- Literature review of recent studies on CF pathophysiology.
- Analysis of current and emerging therapeutic approaches for CF lung disease.
- Synthesis of information on CFTR-targeting therapies and their clinical potential.
Main Results:
- Significant progress has been made in understanding how CFTR mutations lead to lung disease.
- New therapeutic strategies are being developed to target the core CFTR defect.
- Early-phase studies of novel CFTR modulators show promising results.
Conclusions:
- Understanding CF pathophysiology has driven the development of innovative treatments.
- Future CF therapies may correct the underlying genetic abnormality, not just its effects.
- Continued research is crucial to establish the efficacy and long-term benefits of new CF treatments.
Related Concept Videos
01:24Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:29Pharmacogenomics: Identification of New Drug Targets
01:29Microorganisms in Medicine and Therapeutics
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.